National Pharmaceutical Congress celebrates Canadian life sciences leaders
This year’s Canadian Healthcare Marketing Hall of Fame inducts eight industry exemplars (Issue #308; 1400 words, 7 minutes)
The 18th National Pharmaceutical Congress, Canada’s largest gathering for pharmaceutical industry leaders, provides a platform for Canada’s pharma executives to discuss industry trends, network, and celebrate significant achievements. This year’s congress, held on Nov. 6, 2024, at the Mississauga Convention Centre in Mississauga, Ont., maintained the event’s tradition of high-impact presentations and discussions.
A highlight of the event was the 22nd annual Canadian Healthcare Marketing Hall of Fame Awards, a ceremony established to recognize outstanding contributions to healthcare marketing. Each inductee was nominated by peers, affirming their influence and dedication to advancing the industry. This year’s honourees represent diverse roles and accomplishments and embody the core values that make healthcare marketing a unique and impactful profession.
Among those inducted into the 2024 Hall of Fame were:
Corinne Buchanan-Russell, President and Co-founder of Advancing Black Talent in Pharma (ABTiP),
Coleen Coxson, Country General Manager at Alnylam Pharmaceuticals,
Evica Eric, Vice President of Finance & Business Operations at Lundbeck Canada,
Brian Honda, President of AdPharm and Synapse Medical Communications,
Ian Howard, Managing Director of Dermatology Update,
Michael Stone, Country Manager at Merz Therapeutics, and
Robert Tam, General Manager of Taiho Pharma Canada.
The 2024 Phil Diamond Award for Community Service was awarded to Mona Sabharwal, Senior Vice President of Pharmacy Services at Rexall Pharmacy Group, for her exemplary contributions outside her professional role. Due to health reasons, Sabharwal couldn’t attend the ceremony, and her husband, Dr. Aroop Rastogi, accepted the award on her behalf in an emotional tribute. His remarks underscored the depth of her dedication to serving her community.
THIS WEEK 11/12/24
The U.S. FDA granted marketing approval to Autolus Therapeutics' obecabtagene autoleucel (Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adult patients.
Journey Medical Corporation announced that the U.S. FDA approved its minocycline hydrochloride extended-release capsules (Emrosi) for the treatment of inflammatory lesions of rosacea in adults.
Canada's Drug Agency recommended Merck's etanercept (Winrevair) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy for treating adults with World Health Organization Group 1 PAH and Functional Class II or III.
Ottawa’s Carleton University launched a new tech-forward nursing program with the first intake of students starting in the fall of 2025. The university partnered with Queensway Carleton Hospital to transform nursing education and accelerate the entrance of new nurses into the healthcare system.
NOW LISTEN UP: HERE’S JONATHAN SOONG OF AMICUS THERAPEUTICS
In season 13 of the NPC Podcast, Jonathan Soong, General Manager of Amicus Therapeutics, gives insights into being at the forefront of rare disease innovations, patient support programs, and the importance of real-world evidence for rare diseases. Hear him in conversation with podcast hosts Mitch Shannon, Jim Shea, and Mark McElwain.
HEALTHBIZ REWIND
This feature of NPC Healthbiz Weekly looks back at some of the most insightful moments from previous NPC Podcast episodes. In Healthbiz Rewind, you’ll read bold life sci predictions made during the renowned “Prognostication Korner” segment of the NPC Podcast.
Jaclyn Katelnikoff
Clinical Pharmacist
Saskatoon.
Season 12, episode 06
Listen to this episode here
What bold predictions do you have about the life sciences industry over the next 12 to 24 months or even longer?
That's tricky; I think we're in for a bumpy ride. The aging population is growing much faster than the workforce, and we're already being stretched to our limits. At the same time, excessive regulations and red tape bog down our practices. Ideally, we'd see extreme technological advancements within 24 months—though I'm not sure that's even reasonable. We've been using the same software for 15 years without change, and we need documentation to advance at lightning speed to care for the population coming our way. That's my hope; hopefully, it's more than just a prediction.
INTRODUCING DERMATOLOGY.BUSINESS and the DERMATOLOGY.BUSINESS DEEP DIVE PODCAST
Check out Dermatology.Business, the new newsletter from the same fine folks who bring you NPC Healthbiz Weekly. And now you can dive deeper into the Dermasphere with our supplemental podcast. Both are published every other Wednesday at precisely 6:00 a.m. EDT. Dermatology.Business has all the breaking news reported directly from the Dermasphere. Find it here and request your free subscription.
NEXT WEEK
It’s easy to get your no-charge subscription to NPC Healthbiz Weekly. We’ll send each issue to your phone or inbox at 6:00 a.m. sharp each Tuesday.
You are receiving this newsletter because you are a client of Chronicle Companies, attended a National Pharmaceutical Congress live event or webinar, or previously requested a subscription to one of our newsletters. If you no longer wish to subscribe to this newsletter, please email the subject line “Unsubscribe NPC Healthbiz” to health@chronicle.org.
NPC Healthbiz Weekly is published by Chronicle Companies, 701 Ellicott Street, Buffalo, N.Y. 14203. Canadian Office: 1460 The Queensway, Suite 212, Etobicoke, Ont. M8Z 1S4
Mitchell Shannon, Publisher; R. Allan Ryan, Editorial Director; John Evans, Joyce Pitters-Hands, Jeremy Visser, Editors; Cristela Tello Ruiz, New Business Development; Amy Elder, Intern; Shannon Abbott, Conferences Organizer.
Content is copyright (c) 2024, Chronicle LifeSci America Corp., except as indicated. Are you interested in contributing to this newsletter or learning about the Chronicle’s services? Please write to us at health@chronicle.org.
Thanks for reading NPC Healthbiz Weekly. Be sure to subscribe to receive new posts directly to your inbox.